Hemogenyx Pharmaceuticals PLC Announces Result of Annual General Meeting
Hemogenyx Pharmaceuticals PLC Announces Result of Annual General Meeting
LONDON, UNITED KINGDOM / ACCESSWIRE / June 27, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that, at the Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed on a show of hands. The numbers of proxy votes for each resolution submitted prior to the meeting are presented below.
海默格诺克斯药品有限公司（LSE:HEMO）很高兴宣布，在今天早些时候举行的年度股东大会（"AGM"）上，所有决议都已经通过。以下是会议前提交的每个决议的委托代理投票数量：
Proxy Voting Results
委托代理投票结果
Ordinary Resolutions |
Votes for |
% of votes cast for |
Votes Against |
% of votes cast against |
Total votes cast |
Total votes cast as % of ISC (1) |
Votes with-held (2) |
1. To receive and adopt the Company's annual accounts for the year ended 31 December 2023. |
172,981,350 |
99.89 |
189,346 |
0.11 |
173,170,696 |
12.91 |
804,255 |
2. To approve the Directors' Remuneration Report which is set out in the 2023 Annual Report and Accounts. |
155,914,909 |
90.14 |
17,056,623 |
9.86 |
172,971,532 |
12.89 |
1,003,419 |
3. To re-appoint Sir Marc Feldmann as a Director of the Company. |
168,819,296 |
97.51 |
4,316,573 |
2.49 |
173,135,869 |
12.90 |
839,082 |
4. To re-appoint PKF Littlejohn LLP as auditor of the Company to hold office until the conclusion of the next Annual General Meeting of the Company. |
156,805,252 |
99.10 |
1,429,684 |
0.90 |
158,234,936 |
11.79 |
15,740,015 |
5. To authorise the Audit Committee to agree the auditor's remuneration. |
157,329,629 |
90.99 |
15,576,903 |
9.01 |
172,906,532 |
12.89 |
1,068,419 |
6. To authorise the Directors to allot shares pursuant to section 551 of the Companies Act 2006. |
153,328,931 |
88.71 |
19,513,766 |
11.29 |
172,842,697 |
12.88 |
1,132,254 |
Special Resolutions |
Votes for |
% of votes cast for |
Votes against |
% of votes cast against |
Total votes cast |
Total votes cast as % of ISC (1) |
Votes with-held (2) |
7. To disapply pre-emption rights under section 570 of the Companies Act 2006. |
152,661,902 |
88.30 |
20,235,808 |
11.70 |
172,897,710 |
12.89 |
1,077,241 |
8. To approve for calling of general meetings (other than AGMs) on 14 days' notice. |
172,081,747 |
99.38 |
1,080,015 |
0.62 |
173,161,762 |
12.91 |
813,189 |
普通决议事项 |
赞成票数 |
投票的% |
反对票 |
投票反对的% |
投票总数 |
总投票数占ISC%(1) |
弃权票数(2) |
1. 接受并通过公司截至2023年12月31日的年度报告和账目. |
172,981,350 |
99.89 |
189,346 |
0.11 |
173,170,696 |
12.91 |
804,255 |
2. 批准公司2023年年度报告和账目中列出的董事薪酬报告. |
155,914,909 |
90.14 |
17,056,623 |
9.86 |
172,971,532 |
12.89 |
1,003,419 |
3. 重新任命马克·菲尔德曼为公司董事. |
168,819,296 |
97.51 |
4,316,573 |
2.49 |
173,135,869 |
12.90 |
839,082 |
4.为公司重任PKF Littlejohn LLP为其核数师，任期至下一届股东周年大会。 |
156,805,252 |
99.10 |
1,429,684 |
0.90 |
158,234,936 |
11.79 |
15,740,015 |
5.授权审计委员会同意核数师的报酬。 |
157,329,629 |
90.99 |
15,576,903 |
9.01 |
172,906,532 |
12.89 |
1,068,419 |
6.授权董事会根据2006年公司法第551条规定分配股份。 |
153,328,931 |
88.71 |
19,513,766 |
11.29 |
172,842,697 |
12.88 |
1,132,254 |
特别决议 |
赞成票数 |
投票的% |
反对票 |
投票反对的% |
投票总数 |
总投票数占ISC%(1) |
弃权票数(2) |
7. 根据《2006年公司法》第570条取消认购权。 |
152,661,902 |
88.30 |
20,235,808 |
11.70 |
172,897,710 |
12.89 |
1,077,241 |
8. 批准在14天通知后召开股东大会（非周年股东大会）。 |
172,081,747 |
99.38 |
1,080,015 |
0.62 |
173,161,762 |
12.91 |
813,189 |
(1) The Company's issued share capital ("ISC") on 25 June 2024, being the date on which members had to be entered in the register of members of the Company in order to be entitled to attend and vote at the meeting, was 1,341,815,988 ordinary shares.
（1）公司于2024年6月25日的发行股本（“ISC”）是13,418,159,828股普通股，这是成为公司股东名册中的成员并有权参加和投票的日期。
(2) A 'vote withheld' in respect of any resolution is not a vote in law and is not counted in the calculation of the proportion of the votes for and against it.
(2) 对任何决议的“弃权投票”在法律上不算投票，也不计入赞成和反对票的比例计算。
A copy of the resolutions passed has been submitted to the National Storage Mechanism and will shortly be available for inspection at
通过的决议副本已提交至全国存档机制，并将很快可供检查。
Enquiries:
查询：
| Hemogenyx Pharmaceuticals plc | ||
| Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | headquarters@hemogenyx.com | |
| Peter Redmond, Director | peter.redmond@hemogenyx.com | |
| SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 | |
| Matthew Johnson, Vadim Alexandre, Adam Cowl | ||
| Peterhouse Capital Limited | Tel: +44 (0)20 7469 0930 | |
| Lucy Williams, Duncan Vasey, Charles Goodfellow |
| Hemogenyx Pharmaceuticals股份有限公司 | ||
| Vladislav Sandler博士，首席执行官兼联合创始人 | headquarters@hemogenyx.com | |
| 彼得·雷德蒙德，董事 | peter.redmond@hemogenyx.com | |
| SP Angel Corporate Finance LLP | 电话: +44 (0)20 3470 0470 | |
| 马修·约翰逊，伏迪姆·亚历山大，亚当·科尔 | ||
| Peterhouse Capital Limited | 电话: +44 (0)20 7469 0930 | |
| 露西·威廉姆斯，邓肯·瓦西，查尔斯·古德菲洛 |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit .
此信息由英国证券交易所的新闻服务RNS提供。RNS获批由英国金融行为监管局担任英国主要信息提供者。有关使用和分发此信息的条款和条件可能适用。欲了解更多信息，请联系rns@lseg.com或访问。
SOURCE: Hemogenyx Pharmaceuticals PLC
来源：Hemogenyx药品股份有限公司